What the RISC complex is and why it exists
The RNA-induced silencing complex (RISC) is the molecular effector of RNA interference (RNAi) — the gene-silencing mechanism discovered by Fire and Mello (Nobel Prize, 2006) in Caenorhabditis elegans. In animals, RISC is the machinery that executes miRNA-mediated post-transcriptional gene silencing, arguably the most pervasive gene-regulatory mechanism in the metazoan genome. It is estimated that more than 60% of human protein-coding genes contain conserved miRNA target sites in their 3' untranslated regions (UTRs), meaning that RISC-mediated regulation is not a niche pathway but a foundational layer of gene expression control.
The biological rationale for RISC is modularity and reversibility. Rather than relying on transcription factor binding sites (which are fixed in the genome), miRNA-mediated regulation allows the same mRNA to be silenced in one cell type and expressed in another, depending solely on which miRNAs are produced in that cell. This flexibility is essential for development (where miRNA expression patterns change radically between cell lineages) and for adaptive responses to environmental signals (where metabolic cues can alter miRNA expression to reset the transcriptional programme).
miRNA biogenesis: from gene to guide strand
miRNA genes are typically transcribed by RNA Pol II as long primary transcripts called pri-miRNAs, which fold into hairpin structures. The Drosha/DGCR8 microprocessor complex — a nuclear RNase III — cleaves the pri-miRNA to release the ~65 nt hairpin precursor (pre-miRNA). Exportin-5 exports the pre-miRNA to the cytoplasm, where Dicer (another RNase III enzyme, working with TRBP and PACT co-factors) cleaves the pre-miRNA loop, generating a ~22 nt miRNA duplex. This duplex is loaded into the RISC loading complex (RLC), composed of Dicer, TRBP, PACT, and an Argonaute protein (AGO1–4 in humans).
Within the RLC, the duplex is unwound in a strand-selection step: the guide strand (mature miRNA) is retained in the AGO protein, while the passenger strand (miRNA*, the complementary arm) is ejected and degraded. The asymmetry of strand selection is determined by the relative thermodynamic stability of the 5' ends of each strand — the strand with the less stable 5' end is preferentially retained as the guide. HSP90 plays a critical, ATP-dependent role in this loading process, keeping the PIWI domain of AGO in an open conformation that allows duplex loading before closing to grip the guide strand.
Argonaute proteins: the molecular slicer and silencer
The four human AGO proteins (AGO1–4) are the central components of RISC. All four share the same domain architecture: an N-terminal domain, a PAZ domain (which grips the 3' end of the guide strand), a MID domain (which positions the 5' phosphate of the guide strand), and a C-terminal PIWI domain (which has RNase H-like endonuclease activity). Only AGO2 is catalytically active — the others lack the precise arrangement of catalytic residues (Asp597, Asp669, His807, His808 in human AGO2) that constitute the "DEDH" tetrad required for phosphodiester bond cleavage.
Slicing: perfect-complement targets
When a guide strand loaded into AGO2 encounters a target mRNA with near-perfect complementarity (seed region match plus extensive 3' pairing), AGO2 positions the scissile phosphodiester bond of the target between nucleotides 10 and 11 of the guide strand, and the PIWI domain cleaves it. This produces mRNA fragments with a 5'-phosphate and a 3'-hydroxyl that are then rapidly degraded by the cellular RNA decay machinery. This "slicing" mode is the mechanism exploited by exogenous siRNAs (synthetic 21-nt duplexes designed with perfect target complementarity) and is the operational basis of RNAi therapeutics such as inclisiran (targeting PCSK9 mRNA in the liver for cholesterol reduction).
Translational repression and deadenylation: the dominant animal miRNA mechanism
The vast majority of animal miRNA–target interactions involve only partial complementarity — specifically, a 6–8 nt "seed" match at positions 2–7/8 of the guide strand, without extensive 3' pairing. In this configuration, AGO2 cannot execute slicing. Instead, AGO2 recruits GW182 (TNRC6A/B/C in humans) through multiple tryptophan-containing GW/WG repeats in the AGO PIWI domain. GW182 acts as a scaffold that assembles a multiprotein silencing complex on the target mRNA.
GW182 recruits the CCR4-NOT deadenylase complex (comprising CNOT1–9 and the catalytic deadenylases CNOT6/6L and CNOT7/8), which shortens the poly(A) tail of the target mRNA. Poly(A) tail shortening has two consequences: it reduces mRNA stability (the deadenylated mRNA is then decapped by DCP1/DCP2 and degraded 5'→3' by XRN1) and it reduces translational efficiency (because the PABP-eIF4G interaction that promotes ribosome recycling is disrupted). In addition to deadenylation-dependent silencing, GW182 can also repress translation through direct inhibition of ribosomal cap recognition by eIF4E, though the relative contributions of the two mechanisms vary by cell type and target context.
Key miRNAs at the intersection of spirulina biology and inflammation
miR-146a: the NF-κB brake
miR-146a is one of the most important negative feedback regulators of innate immune signalling. Its expression is induced by NF-κB (the very pathway it inhibits), creating a delayed negative feedback loop. miR-146a targets IRAK1 (IL-1 receptor-associated kinase 1) and TRAF6 (TNF receptor-associated factor 6) — two essential signal transducers between TLR/IL-1R receptors and NF-κB. By reducing IRAK1 and TRAF6 protein levels post-transcriptionally, miR-146a progressively attenuates TLR-driven NF-κB responses during sustained inflammatory stimulation. Loss of miR-146a in mice leads to myelo-proliferative disease and eventual haematopoietic tumours, confirming its tumour-suppressive and anti-inflammatory roles in vivo.
miR-155: the NF-κB amplifier
miR-155 is also NF-κB-inducible but acts in the opposite direction: it amplifies inflammatory signalling by suppressing anti-inflammatory targets including SHIP1 (inositol phosphatase that limits PI3K-Akt signalling downstream of TLRs), SOCS1 (JAK-STAT inhibitor), and BCL-6 (transcriptional repressor of inflammatory genes). miR-155 overexpression is characteristic of many B-cell lymphomas and promotes Th1/Th17 T-cell differentiation. miR-155 can be viewed as a gain-of-signal miRNA for NF-κB pathway activity.
The miR-146a/miR-155 balance is a useful metric of macrophage and immune cell inflammatory state. Anti-inflammatory stimuli tend to raise miR-146a and lower miR-155; pro-inflammatory stimuli do the opposite.
miR-21: the anti-apoptotic oncomiR
miR-21 is among the most consistently overexpressed miRNAs across human cancers. Its targets include the tumour suppressors PTEN (the phosphatase that opposes PI3K signalling), PDCD4 (programmed cell death protein 4, a pro-apoptotic translation inhibitor), and RECK (reversion-inducing cysteine-rich protein with Kazal motifs, an anti-invasive factor). By suppressing these targets, miR-21 promotes cell survival, PI3K-Akt-mTOR signalling, and invasiveness. miR-21 is also NF-κB-inducible, connecting inflammation to cancer progression through miRNA dysregulation.
let-7 family: tumour suppressors targeting RAS
The let-7 miRNA family (13 members in humans, from let-7a to let-7m plus miR-98) was among the first miRNAs identified in C. elegans (where its loss causes developmental defects). In mammals, let-7 family members collectively target RAS family oncogenes (KRAS, NRAS, HRAS), HMGA2 (chromatin-remodelling oncoprotein), and MYC. Let-7 expression is suppressed in many cancers, and its restoration in lung cancer, colon cancer, and leukaemia cell lines reduces proliferation and tumour formation. The RNA-binding protein LIN28 (highly expressed in stem cells and cancer stem cells) directly inhibits let-7 biogenesis by binding pre-let-7 and blocking Dicer processing, creating a LIN28/let-7 feedback axis that governs the boundary between stem-cell identity and differentiation.
The metabolite-miRNA connection
Gene regulation does not occur in a metabolic vacuum. Several metabolic intermediates are direct regulators of the chromatin-modifying enzymes that control miRNA gene expression.
S-adenosylmethionine (SAM), the universal methyl donor produced in the methionine cycle, is the substrate for DNA methyltransferases (DNMTs). DNMT-mediated CpG methylation in miRNA promoters can silence miRNA genes — this is the mechanism by which miR-127, miR-34b/c, and many other tumour-suppressive miRNAs are silenced in cancer. SAM availability thus directly influences the methylation-dependent accessibility of miRNA genes.
Conversely, alpha-ketoglutarate (α-KG), a TCA cycle intermediate, is a required cofactor for TET enzymes (TET1/2/3) that oxidise 5-methylcytosine to 5-hydroxymethylcytosine, initiating active DNA demethylation and thus potentially re-expressing methylation-silenced miRNA genes. The metabolic flux through the TCA cycle — governed by nutrient availability, AMPK status, and mitochondrial function — therefore connects cellular energy state to miRNA expression patterns via α-KG/TET demethylation.
This metabolite-epigenome-miRNA axis is the mechanistic basis for diet-responsive gene regulation: changes in one-carbon metabolism, TCA cycle flux, and acetyl-CoA availability (for histone acetylation at miRNA gene promoters) propagate to changes in miRNA transcription, which then change the protein expression landscape.
Spirulina and miRNA-RISC biology
AMPK, miR-33, and cholesterol efflux
miR-33a and miR-33b are intronic miRNAs encoded within the SREBP1 and SREBP2 genes, respectively. They target ABCA1 and ABCG1 — the cholesterol transporters responsible for effluxing cholesterol from macrophages and hepatocytes to HDL particles. When AMPK is activated, it phosphorylates and inhibits SREBP processing, and the resulting reduction in SREBP-driven transcription reduces the co-transcription of miR-33 with its host gene. Lower miR-33 levels de-repress ABCA1/G1 expression, increasing cholesterol efflux capacity. This is the mechanistic basis for claims that AMPK activators improve HDL biology, and spirulina's AMPK-activating effects — mediated via phycocyanin and phycocyanobilin — would be predicted to produce a modest miR-33 suppression and corresponding increase in ABCA1 protein.
Anti-inflammatory miRNA profile and spirulina
The overall anti-inflammatory effect of spirulina — NF-κB suppression, reduced TNF-α and IL-6 production, and macrophage M2 skewing — is consistent with an upregulation of miR-146a and downregulation of miR-155 in macrophages and other immune cells. Both shifts represent adaptations to a lower NF-κB signalling environment. Whether spirulina compounds directly induce miR-146a transcription (through NF-κB-independent mechanisms) or whether the miRNA changes are simply downstream consequences of reduced NF-κB activity cannot be determined from available data. At least one animal study has measured miR-155 reduction in spirulina-treated inflammatory models, but the dataset is too limited to draw firm conclusions about directionality or the involvement of RISC loading.
Honest uncertainty about AGO2 and RISC machinery
There is no evidence that spirulina compounds interact with AGO2, GW182, Dicer, Drosha, or any other core RISC component. The biophysics of phycocyanobilin suggest it could intercalate into nucleic acid duplexes — which might theoretically affect miRNA loading thermodynamics — but this is highly speculative and has not been tested. The mechanistic connections between spirulina and miRNA biology currently run through metabolic regulators (AMPK, NF-κB, SAM cycling) rather than through direct RISC interaction. This is not unusual for nutritional compounds; direct RISC modulation is the province of synthetic oligonucleotides (like anti-miR antagomirs or miRNA mimics), not bioactive metabolites.